Find Reports
Select Report Type
Reimbursement Review
Displaying 1101 - 1125 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Vyloy | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | PC0338-000 | ||||
| Keytruda | pembrolizumab | Non-small cell lung cancer (NSCLC) | Active | PC0369-000 | ||||
| Keytruda | pembrolizumab | Unresectable or metastatic MSI-H or dMMR solid tumors | Active | PC0377-000 | ||||
| Jemperli | dostarlimab | Endometrial cancer | Active | PC0381-000 | ||||
| TBC | crovalimab | paroxysmal nocturnal hemoglobinuria (PNH) | Active | SR0858-000 | ||||
| Signifor LAR | pasireotide | Acromegaly, adults | Active | SR0859-000 | ||||
| TBC | fecal microbiota | Clostridioides difficile infection, prevention | Active | SR0850-000 | ||||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | PC0316-000 | ||||
| Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | SR0797-000 | ||||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | SR0751-000 | ||||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | SR0753-000 | ||||
| Pemazyre | pemigatinib | Cholangiocarcinoma | Active | PC0391-000 | ||||
| Polivy | polatuzumab vedotin | Large B-cell lymphoma | Active | PC0397-000 | ||||
| Opzelura | ruxolitinib | atopic dermatitis | Active | SR0807-000 | ||||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | SR0786-000 | ||||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | SR0804-000 | ||||
| TBC | risperidone | Schizophrenia, adults | Suspended | SR0811-000 | ||||
| Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | SR0824-000 | ||||
| Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0004-000 | |||
| Imfinzi | durvalumab | resectable non-small cell lung cancer (NSCLC) | Suspended | PC0372-000 | ||||
| TBC | garadacimab | Hereditary angioedema (HAE) | Active | SR0860-000 | ||||
| TBC | donanemab | Alzheimer's disease | Suspended | SR0857-000 | ||||
| Dificid | fidaxomicin | Clostridium difficile infection | N/A | Withdrawn | SF0847-000 | |||
| N/A | nab-paclitaxel | Gastrointestinal cancer | Reimburse with clinical criteria and/or conditions | Complete | PX0360-000 | |||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | SR0762-000 |
Health Technology Review
Displaying 576 - 589 of 589
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 1101 - 1125 of 2093
Please scroll or swipe to the right to view the full content.